Amit D Raval1, Ami Vyas2. 1. Healthcore Inc, Wilmington, DE, USA. 2. Department of Pharmacy Practice, College of Pharmacy, University of Rhode Island, Kingston, RI, USA.
Abstract
BACKGROUND: Data on trends of diabetes medications use are sparse, outdated, and limited to prescription data. We determined trends in diabetes medication use among US individuals with diabetes during 2008-2015. METHODS: We used 2008-2015 Medical Expenditure Panel Survey to examine diabetes medication utilization among individuals aged ≥18 years with diabetes. Prescription medications were classified based on therapeutic class and subclass using Multum Lexicon database. RESULTS: From 2008 to 2015, use of any diabetes medication (81.4% vs. 87%), metformin (47.8% vs. 59.0%), and insulin (23.0% vs. 31.0%) increased, whereas, use of sulfonylurea (36.0% vs. 29.0%) and thiazolidinedione (21% vs. 9.0%) declined. A linear increase was observed in the uptake of dipeptidyl peptidase-4 (DPP-4) inhibitors from 6.2% in 2008 to 12.4% in 2015; glucagon-like peptide-1 (GLP-1) receptor agonists from 2.5% in 2008 to 4.4% in 2015 and sodium glucose transporter-2 (SGLT2) inhibitors from 0.8% in 2014 (the first SGLT2 inhibitors approval year) to 4.4% in 2015. Monotherapy use increased from 50.6% to 56.4% during 2008-2015, while triple therapy use declined. CONCLUSIONS: Metformin, insulin and sulfonylureas remained the top-three prescribed classes of diabetes medications. Increased use of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT2 inhibitors was offset by decline in TZDs use.
BACKGROUND: Data on trends of diabetes medications use are sparse, outdated, and limited to prescription data. We determined trends in diabetes medication use among US individuals with diabetes during 2008-2015. METHODS: We used 2008-2015 Medical Expenditure Panel Survey to examine diabetes medication utilization among individuals aged ≥18 years with diabetes. Prescription medications were classified based on therapeutic class and subclass using Multum Lexicon database. RESULTS: From 2008 to 2015, use of any diabetes medication (81.4% vs. 87%), metformin (47.8% vs. 59.0%), and insulin (23.0% vs. 31.0%) increased, whereas, use of sulfonylurea (36.0% vs. 29.0%) and thiazolidinedione (21% vs. 9.0%) declined. A linear increase was observed in the uptake of dipeptidyl peptidase-4 (DPP-4) inhibitors from 6.2% in 2008 to 12.4% in 2015; glucagon-like peptide-1 (GLP-1) receptor agonists from 2.5% in 2008 to 4.4% in 2015 and sodium glucose transporter-2 (SGLT2) inhibitors from 0.8% in 2014 (the first SGLT2 inhibitors approval year) to 4.4% in 2015. Monotherapy use increased from 50.6% to 56.4% during 2008-2015, while triple therapy use declined. CONCLUSIONS:Metformin, insulin and sulfonylureas remained the top-three prescribed classes of diabetes medications. Increased use of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT2 inhibitors was offset by decline in TZDs use.
Entities:
Keywords:
Medical Expenditure Panel Survey; diabetes; insulin; metformin; trends
Authors: Stephanie Navarro; Xiaohui Hu; Aaron Mejia; Carol Y Ochoa; Trevor A Pickering; Leslie Ballas; Albert J Farias Journal: Cancer Causes Control Date: 2022-01-15 Impact factor: 2.506
Authors: Clemens Engler; Marco Leo; Bernhard Pfeifer; Martin Juchum; Di Chen-Koenig; Karin Poelzl; Hans Schoenherr; David Vill; Juliana Oberdanner; Egon Eisendle; Klaus Middeldorf; Bernhard Heindl; Hannes Gaenzer; Gerald Bode; Karl Kirchmeyr; Guenther Ladner; Lisa Rieger; Ursula Koellensperger; Andrea Schwaiger; Florian Stoeckl; Guenther Zangerl; Monika Lechleitner; Irmgard Delmarko; Wilhelm Oberaigner; Clemens Rissbacher; Herbert Tilg; Christoph Ebenbichler Journal: BMJ Open Diabetes Res Care Date: 2020-09